BioinvestGPT

BioinvestGPT ApS · Research use only

NCT06150924 (Lorundrostat in hypertension and Chronic Kidney Disease with…): BVCT ex-ante prediction vs. reported outcome

On 26 Jul 2024, BioinvestGPT's BVCT predicted technical success and commercial success for this trial. The 17 Jun 2025 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially probably sufficient.

Clinical Trial

NCTID
NCT06150924
Acronym
Explore-CKD
Drug Name
Lorundrostat
Drug MoA
aldosterone synthase inhibitor
Drug Modality
small molecule
Drug Class
Best-In-Class
Therapeutic Area
Cardiovascular Diseases
Indication
hypertension and Chronic Kidney Disease (CKD) with albuminuria
Human Patients
60
Sponsor
Mineralys Therapeutics
Phase
Phase 2

Prediction of , index 1393

Prospective Prediction
Prediction Index
1393
Prediction Date
Commercial Prediction
SUCCESS (commercially sufficient additive clinical benefit in AOBP SBP for lorundrostat + dapagliflozin combotherapy adjunctive treatment which would be non-superior to lorundrostat monotherapy adjunctive treatment)
Technical Prediction
SUCCESS (statistically significant additive clinical benefit in AOBP SBP)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
326 days in advance
Readout Data Interpretation
lorundrostat + dapagliflozin achieved a 7.5 mmHg placebo-adjusted reduction in systolic blood pressure at week 4 (p=0.0024)
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially probably sufficient
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Randomized, Crossover, Double Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors, in Adults With Hypertension and Chronic Kidney Disease With Albuminuria
Phase
Phase 2
Status
Completed
Enrollment
60
Lead sponsor
Mineralys Therapeutics Inc.
Conditions
Chronic Kidney Disease
Interventions
DRUG: Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD; DRUG: Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD
Design
Randomized · Crossover · Double
Primary purpose
Treatment
Start
2023-12-14
Primary completion
2025-02-27
Completion
2025-04-23
Results first posted
2026-06-03
Primary outcomes
  • Placebo-adjusted Change From Baseline in Automated Office Blood Pressure (AOBP) Systolic Blood Pressure (SBP) at Week 4 (Baseline to Week 4)

NCT06150924 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials